Gilead Quarterly Profit Misses on Low Hepatitis C Drug Sales

Gilead Quarterly Profit Misses on Low Hepatitis C Drug Sales


Gilead Sciences Inc. posted third-quarter profit that missed analysts' estimates amid steadily declining sales of its hepatitis C drugs, though it isn't rushing to fill its pipeline with deals. While Epclusa, the company's newest drug for the potentially fatal liver infection, outperformed expectations, sales of hepatitis C treatments overall totaled $3.33 billion, Gilead said Tuesday in a statement, lower than the $3.66 billion average projection.



from Biotech News